Dr Joaquin Mateo (Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain), Dr Andrew Parsonson (Macquarie University Hospital, Sydney, Australia) and Dr Capucine Baldini (Gustave Roussy, Villejuif, France) touch on significant advancements in prostate cancer treatments over the last two decades, focusing on hormonal agents, chemotherapy, and then look at new therapies like antibody-drug conjugates and T-cell engagers.

They highlight promising trial data from a B7-H3 targeting ADC study and stress the importance of biomarkers for patient selection.

Dr Baldini also talks about her study results looking at a KLK2/CD3E-targeting bispecifci antibody in metastatic castration-resistant prostate cancer.

The session concludes with an optimistic outlook on combination treatments and adapting to new mechanisms of action (MOAs) to enhance patient outcomes.